Oncolytics Biotech Inc ONCY

Flu virus augment vaccines

[Noteable]

Mechanism demonstrates how ONCY's pelareorep "primes" the immune system in advance of immune checkpoint inhibitors, and other immuno-oncology agents, including mRNA vaccines being developed for cancer treatments.

“Our immune system actually evolved to combat viruses,” study lead Kevin McCarthy, Ph.D., told Fierce Biotech Research in an interview. “If we understand how it evolved in those individuals who had very strong responses, then maybe we can help guide the evolution of everybody’s immune system to make similar responses.”

https://www.fiercebiotech.com/research/newly-identified-flu-antibodies-could-form-basis-better-vaccines

[Noteable]

"One stratregy to enhance T cell priming / tumor immunogenicity is to increase the amount of tumor neoantigens available to T cell", which has been demonstrated by ONCY's pelareorep, and in doing so, reversing T-cell exhaustion. https://www.researchgate.net/publication/376712603_Overcoming_Resistance_Mechanisms_to_Immune_Checkpoint_Inhibitors_Leveraging_the_Anti-Tumor_Immune

[Noteable]

This was from ONCY's November transcript. "And what we were able to demonstrate is in the responders, those TILs, we could see those clones expanding in the blood. So we know we're actually getting an expansion of preexisting T cells that do recognize the tumor, and we can look at that as early as two to three weeks."

[CMHarring218431]

In your estimation, are the indications concerning Pela, equal to or ahead of Candel which has achieved a Fast Track designation from the FDA. Ya know,in terms of survival rate and other comparable positive results or are they both on opposite tracks to treatment and success? Just trying to gain a little insight into the science because with the lack of prior successes in treatment of Pancreatic C

[askretka]

https://www.candeltx.com/pipeline/ Candel Therapeutics is going after non-metastatic pancreatic cancer.